drugset / Trial / NCT07223671

Study to Evaluate the Effect of Repotrectinib on the Drug Levels of Transporter and CYP P450 Probe Substrates in Healthy Adult Participants

NCT07223671

Phase 1 Completed 30 enrolled Bristol-Myers Squibb
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study if to evaluate the effect of Repotrectinib on the drug levels of transporter and CYP P450 probe substrates in healthy adult participants.

Timeline

Start
2025-12-31
Primary completion
2026-02-19
Completion
2026-03-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupropion Small molecule
Subject Digoxin Other / unclassified
Subject Flurbiprofen Small molecule
Subject Metformin Small molecule
Subject Omeprazole Other / unclassified
Subject Repotrectinib Small molecule
Subject Rosuvastatin Small molecule

Indications

No indication recorded.